clopidogrel has been researched along with Carcinoma, Hepatocellular in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerwins, P; Heindryckx, F; Kopsida, M; Pavlović, N | 1 |
| Imada, K; Mizutani, C; Nogami, K; Shimizu, T | 1 |
| Andreu-Oller, C; Friedman, SL; Heikenwälder, M; Higuera, M; Llovet, JM; Moeini, A; Montironi, C; Peix, J; Pfister, D; Pinyol, R; Ramadori, P; Sia, D; Solé, M; Torrecilla, S; Tovar, V | 1 |
| Guidotti, LG; Iannacone, M; Sitia, G | 1 |
| Tan-Shalaby, JL | 1 |
| Chao, Y; Chen, CC; Chen, TJ; Hu, YW; Huang, YH; Huo, TI; Lee, PC; Lin, HC; Liu, CJ; Su, CW; Wu, JC; Yeh, CM | 1 |
| Cheng, C; Guo, H; Li, B; Liu, Y; Liu, YJ; Xu, J; Zhang, R; Zhao, Y; Zhou, C | 1 |
| Aiolfi, R; Chisari, FV; Di Lucia, P; Esposito, A; Fiocchi, A; Guidotti, LG; Iannacone, M; Mainetti, M; Mingozzi, F; Ruggeri, ZM; Sitia, G | 1 |
| Greenhill, C | 1 |
| Shi, D; Song, X; Yan, B; Yang, D; Yang, J | 1 |
10 other study(ies) available for clopidogrel and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment.
Topics: Animals; Blood Platelets; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Clopidogrel; Disease Models, Animal; Endothelial Cells; Female; Hepatic Stellate Cells; Humans; Liver Neoplasms; Male; Mice; Signal Transduction; Tumor Microenvironment | 2021 |
[Acquired hemophilia A with high-titer factor VIII inhibitor developing subsequent to clopidogrel administration].
Topics: Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clopidogrel; Factor VIII; Hemophilia A; Humans; Liver Neoplasms; Male | 2019 |
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Cell Transformation, Neoplastic; Clopidogrel; Diethylnitrosamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indoles; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice, Inbred C57BL; Transcriptome; Tumor Escape; Tumor Microenvironment | 2019 |
Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Aspirin; Blood Platelets; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proliferation; Clopidogrel; Disease Models, Animal; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Mice; Platelet Aggregation Inhibitors; Ticlopidine | 2013 |
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Ticlopidine; Time Factors; Tomography, X-Ray Computed | 2014 |
Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Clopidogrel; Disease-Free Survival; Female; Gastrointestinal Hemorrhage; Hepatectomy; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Survival Rate; Taiwan; Ticlopidine | 2016 |
Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding.
Topics: Adenosine Diphosphate; Aged; Animals; Blood Platelets; Carcinogenesis; Carcinoma, Hepatocellular; Cell Differentiation; Clopidogrel; Female; Hep G2 Cells; Humans; Intercellular Junctions; Liver Neoplasms; Male; Mice; Mice, SCID; Middle Aged; P-Selectin; Platelet Activation; Protein Binding; RNA, Small Interfering; Ticlopidine; Transcription Factor 4; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
Topics: Analysis of Variance; Animals; Aspirin; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase 2; Hepatitis B, Chronic; Liver; Liver Neoplasms; Membrane Proteins; Mice; Mice, Transgenic; Platelet Aggregation Inhibitors; Real-Time Polymerase Chain Reaction; Ticlopidine | 2012 |
Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?
Topics: Animals; Carcinoma, Hepatocellular; Chemoprevention; Clopidogrel; Disease Models, Animal; Disease Progression; Hepatitis B, Chronic; Humans; Liver Neoplasms; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Clopidogrel; Dose-Response Relationship, Drug; Female; Hepatocytes; Humans; Interleukin-6; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oseltamivir; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine | 2007 |